DBV Technologies (DBVT) Restructuring Costs (2020 - 2021)
DBV Technologies (DBVT) posted Restructuring Costs of -$920000.0 for Q4 2021, down 136.09% sequentially from $2.5 million in Q4 2020, and down 136.09% YoY from $2.5 million in Q4 2020.
Powered by 
Analysis
DBV Technologies (DBVT) Restructuring Costs (2020 - 2021) Analysis & Trends
DBV Technologies has reported Restructuring Costs for 2 years, with the latest figure at -$920000.0 in Q4 2021.
- Quarterly Restructuring Costs fell 136.09% year-over-year to -$920000.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $1.6 million (changed N/A YoY) and the FY2021 annual result came in at -$920000.0, down 103.91% from the prior year.
- Restructuring Costs declined to -$920000.0 in Q4 2021 per DBVT's latest filing, from $2.5 million in the prior quarter.
- Over five years, Restructuring Costs peaked at $21.3 million in Q2 2020 and troughed at -$920000.0 in Q4 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 10 | DBV Technologies | 5.85 Bn | 5.67 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | -920,000.00 |
| Dec 31, 2020 | 2.55 Mn |
| Sep 30, 2020 | -286,000.00 |
| Jun 30, 2020 | 21.29 Mn |